Literature DB >> 18226951

Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis.

Richard P Allen1, James R Connor, Keith Hyland, Christopher J Earley.   

Abstract

BACKGROUND: Abnormally high CSF 3-OMD occurs frequently for RLS patients indicating either increased l-dopa synthesis, limitations in l-dopa decarboxylation or increased MAT/COMT activity, or some combination of these. Increased tyrosine hydroxylase activity was found on both the RLS autopsy and the rodent iron-deprivation model of RLS, suggesting increased DA synthesis in RLS. We, therefore, hypothesized elevated 3-OMD in RLS results from increased DA synthesis and that this should occur accordingly with increased HVA. It would then also reflect both the more severe iron insufficiency pathology of RLS and greater clinical severity, shown by the objective measure of PLMS/hr.
METHODS: Patients off RLS medications and matched controls had lumbar punctures at either 10 a.m. or 10 p.m.; RLS patients were grouped by normal or abnormally high 3-OMD (>10 nmol/l).
RESULTS: Forty-nine RLS patients (30 high, 19 normal 3-OMD) and 36 age- and gender-matched controls, analyzed separately by time of CSF collection, did not significantly differ in age or gender. RLS patients with high 3-OMD had significantly higher CSF HVA, while those with normal 3-OMD had consistently lower CSF HVA than controls. CSF ferritin was consistently lower compared to controls for the high 3-OMD but not the normal 3-OMD RLS patients. The PLMS/hr was significantly higher for RLS patients with high compared to normal 3-OMD, indicating high 3-OMD patients had more severe RLS.
CONCLUSIONS: Abnormal elevation in 3-OMD for RLS patients may reflect increased dopamine synthesis for more severe but perhaps not mild RLS. These differences in the putative dopamine pathology of RLS may indicate different phases or expression of RLS biology or different underlying disease processes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226951      PMCID: PMC2655320          DOI: 10.1016/j.sleep.2007.11.012

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  19 in total

1.  Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients.

Authors: 
Journal:  Sleep Med       Date:  2001-01       Impact factor: 3.492

2.  Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome.

Authors:  I Eisensehr; T C Wetter; R Linke; S Noachtar; H von Lindeiner; F J Gildehaus; C Trenkwalder; K Tatsch
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

3.  Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

4.  Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.

Authors:  Markku Partinen; Kari Hirvonen; Leni Jama; Anniina Alakuijala; Christer Hublin; Ilkka Tamminen; Juergen Koester; Juergen Reess
Journal:  Sleep Med       Date:  2006-07-03       Impact factor: 3.492

5.  Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.

Authors:  Simon Cervenka; Sven E Pålhagen; Robert A Comley; Georgios Panagiotidis; Zsolt Cselényi; Julian C Matthews; Robert Y Lai; Christer Halldin; Lars Farde
Journal:  Brain       Date:  2006-07-01       Impact factor: 13.501

6.  Validation of the Johns Hopkins restless legs severity scale.

Authors:  R P. Allen; C J. Earley
Journal:  Sleep Med       Date:  2001-05       Impact factor: 3.492

7.  SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep.

Authors:  Martin Michaud; Jean-Paul Soucy; Allal Chabli; Gilles Lavigne; Jacques Montplaisir
Journal:  J Neurol       Date:  2002-02       Impact factor: 4.849

8.  CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome.

Authors:  C J Earley; K Hyland; R P Allen
Journal:  Mov Disord       Date:  2001-01       Impact factor: 10.338

9.  The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.

Authors:  H Tohgi; T Abe; T Kikuchi; S Takahashi; Y Nozaki
Journal:  Neurosci Lett       Date:  1991-10-28       Impact factor: 3.046

10.  Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients.

Authors:  Karin Stiasny-Kolster; J Carsten Möller; Johannes Zschocke; Oliver Bandmann; Werner Cassel; Wolfgang H Oertel; Georg F Hoffmann
Journal:  Mov Disord       Date:  2004-02       Impact factor: 10.338

View more
  33 in total

Review 1.  Update in restless legs syndrome.

Authors:  Rachel E Salas; Charlene E Gamaldo; Richard P Allen
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

Review 2.  Pathophysiology of restless legs syndrome: evidence for iron involvement.

Authors:  James R Connor
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

3.  Restless legs syndrome: pathophysiology and treatment.

Authors:  William G Ondo
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

4.  The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome.

Authors:  Christopher J Earley; Hiroto Kuwabara; Dean F Wong; Charlene Gamaldo; Rachel Salas; James Brasic; Hayden T Ravert; Robert F Dannals; Richard P Allen
Journal:  Sleep       Date:  2011-03-01       Impact factor: 5.849

Review 5.  Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.

Authors:  Christopher J Earley; George R Uhl; Stefan Clemens; Sergi Ferré
Journal:  Sleep Med       Date:  2016-06-27       Impact factor: 3.492

6.  Periodic limb movements in tetraplegia.

Authors:  Annemieke Emma Josina Peters; Lysanne van Silfhout; Marnie Graco; Rachel Schembri; Dick Thijssen; David J Berlowitz
Journal:  J Spinal Cord Med       Date:  2017-05-02       Impact factor: 1.985

7.  BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome.

Authors:  Shangru Lyu; Atbin Doroodchi; Hong Xing; Yi Sheng; Mark P DeAndrade; Youfeng Yang; Tracy L Johnson; Stefan Clemens; Fumiaki Yokoi; Michael A Miller; Rui Xiao; Yuqing Li
Journal:  Brain Struct Funct       Date:  2020-05-28       Impact factor: 3.270

8.  Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome.

Authors:  Richard P Allen; Christopher J Earley; Byron C Jones; Erica L Unger
Journal:  Sleep Med       Date:  2020-02-05       Impact factor: 3.492

Review 9.  Restless Leg Syndrome/Willis-Ekbom Disease Pathophysiology.

Authors:  Richard P Allen
Journal:  Sleep Med Clin       Date:  2015-07-15

10.  Tourette syndrome and klippel-feil anomaly in a child with chromosome 22q11 duplication.

Authors:  Raymond A Clarke; Zhi Ming Fang; Ashish D Diwan; Donald L Gilbert
Journal:  Case Rep Med       Date:  2009-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.